EMA recommends daraxonrasib for metastatic pancreatic cancer
European Medicines Agency Recommends Daraxonrasib for Metastatic Pancreatic Cancer
On October 15, 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending marketing authorization for daraxonrasib as a treatment for metastatic pancreatic cancer.
-
Key Clinical Takeaways:
- The European Medicines Agency committee recommended daraxonrasib for adults with metastatic pancreatic cancer who have undergone at least one prior therapy.
- Clinical trial data indicate the treatment achieves a median overall survival of 12.4 months, compared to 6.7 months with standard chemotherapy.
- The regulatory review used a accelerated pathway under the Cancer Medicines Pathfinder project, reducing evaluation time to under 150 days.
Daraxonrasib Doubles Progression-Free Survival in Phase III Trial
The positive opinion from the European regulatory body follows a 500-patient international Phase III trial where 92 percent of participants presented with a Ras G12 mutation. Progression-free survival reached 7.2 months in the treatment arm versus 3.6 months for chemotherapy. Developed as an inhibitor of Ras proteins, daraxonrasib binds to cyclophilin A to form a complex that blocks Ras activity, thereby slowing tumor growth and inducing cancer cell death.
Commercial Approval and Financial Realities for Patients
While European regulators advance the review, high treatment costs pose substantial barriers for individual patients. Cristina Giai Pron, a former successful canoeist who achieved a world bronze, a European bronze, multiple Italian championship titles, and five Olympic appearances with a fourth-place finish at Atlanta 1996, described the financial obstacle of accessing therapies in Italy, noting that she is currently following a therapy with a cost of 15,000 euros per month. Wholesale list prices in the United States sit near 39,800 dollars for a 30-day supply. Following the recommendation from the European Medicines Agency, pricing and reimbursement decisions remain subject to negotiations by individual member states.
EMA Evaluation Nears Final European Commission Authorization
The European Medicines Agency evaluation was completed in under 150 days through a progressive data review process. Manufacturing capacity at the developing company, Revolution Medicines, and potential pricing strategies tied to international policy dynamics may influence market availability across European health systems as the European Commission prepares its final authorization steps.
Other European Regulatory Decisions
During the same October 12 to 15, 2026 meeting, the Committee for Medicinal Products for Human Use issued positive opinions for six new medicines in total, alongside five therapeutic indication extensions and a public health decision regarding Nyxoid (naloxone) nasal spray for known or suspected opioid overdoses involving substances such as heroin and morphine, recommending its availability without a medical prescription. The additional authorizations include Neuzafy (filgrastim) for neutropenia in adults and children, Kizfizo (temozolomide) for glioblastoma multiforme in adults and malignant gliomas in children, as well as positive opinions for the expansion of indications for Kyinsu (insulin icodec and semaglutide) in type 2 diabetes and the AstraZeneca H5N1 pandemic influenza vaccine.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.